Introduction {#s1}
============

With a new era of immuno-oncology on the horizon, numerous cancer patients have benefited from the great advances in immunotherapy, especially the discovery of immune checkpoint inhibitors (ICIs), such as cytotoxic T lymphocyte-associated protein 4, programmed cell death 1, and programmed cell death ligand 1 inhibitors ([@B23]). However, the great advantages of these immunotherapeutic strategies are also hampered by major limitations, which restrict them from benefiting a broader range of cancer patients. For example, only 20% of patients with advanced carcinoma (except Hodgkin's lymphoma and melanoma) would benefit from programmed cell death 1 or programmed cell death ligand 1 inhibitors ([@B6]). Similarly, the clinical response rate is very low even in patients receiving anti-CTLA4 therapy for unresectable or metastatic melanoma (the first approved indication of anti-CTLA4 therapy) ([@B57]). Meanwhile, patients receiving ICIs, whether in single drug or in combination, would experience unique immune-related adverse events, ranging from mild adverse effect to potentially life-threatening events ([@B15]). Hence, immunotherapeutic strategies employing other potential mechanisms are worthy of further exploring.

*Echinococcus granulosus*, a canine tapeworm responsible for zoonotic cystic echinococcosis (CE; also termed hydatid disease), has haunted human kind for centuries ([@B71]). *E. granulosus* is still highly epidemic in South America, Mediterranean countries, eastern Africa, Central Asia, and Northwestern China, with human incidence as high as 50 *per* 100,000 person-years according to a report from the World Health Organization ([@B11]). However, after the astonishingly low incidence of CE was incidentally found in patients with solid tumor in Turkey ([@B1]), accumulating evidence have suggested that *E. granulosus* may exhibit anticancer effect through host immune system, which may be employed as an immunotherapeutic strategy against cancer ([@B56]).

*E. Granulosus* Against Cancer: Incidental Findings to Accumulating Evidences {#s1_1}
-----------------------------------------------------------------------------

Various helminths have been proven to be a carcinogenic agent in human, such as the liver fluke *Clonorchis sinensis* and *Opisthorchis viverini* (causative agents of cholangiocarcinoma) ([@B25]) and the blood fluke *Schistosoma japonicum* (well-known risk factor for liver carcinoma and colorectal cancer) ([@B64]; [@B31]), *Schistosoma mansoni* (suspected risk factor for colorectal cancer) ([@B2]), and *Schistosoma haematobium* (which leads to bladder cancer) ([@B9]). On the other hand, accumulating evidence suggested that certain helminth infection could induce anticancer activities, such as the pork worm *Trichinella spiralis*, which can protect infected mice against tumor growth and metastasis ([@B34]).

Coexistence of *E. granulosus* infection and cancer has been broadly reported, such as coexistence with hepatocellular carcinoma ([@B10]; [@B78]; [@B40]), lung carcinosarcoma ([@B46]), liver mucinous cystadenoma ([@B48]), renal sarcoma ([@B7]), renal adenocarcinoma ([@B45]), or ovarian epithelial tumor and lymphoepithelioma-like gastric carcinoma ([@B30]). The exact relationship between *E. granulosus* and cancer, however, has long been unclear until the last decade, when an epidemiological study on patients with CE occasionally found a negative correlation between CE and solid tumors ([@B1]). This extraordinary phenomenon, although still in debate ([@B51]), has led to a hypothesis that infection of *E. granulosus* may elicit protective effect against cancer. Subsequently, results from studies carried out by different research groups have supported this hypothesis. It has been demonstrated that, for example, protoscolices in hydatid cyst (the larval stage of *E. granulosus*) could induce cell death in WEHI-164 fibrosarcoma cell *in vitro* ([@B19]). Moreover, vaccination with hydatid fluid induced tumor regression in a mouse model with experimental CT26 colon cancer ([@B8]). In addition, simultaneously injection of alive protoscolices and melanoma cell could result in significantly reduced tumor growth compared with control group in a mouse model ([@B16]). Similarly, intraperitoneal hydatidosis established by infection of protoscolices could inhibit DMBA-induced mammary tumorigenesis in rats ([@B3]). As an indirect evidence, sera from patients with hydatid disease was cytotoxic to lung cancer cell line but had no effect on fibroblast cells ([@B35]). Collectively, these evidences suggested that *E. granulosus* may elicit protective effect against certain cancer types *in vitro* and *in vivo*.

Mechanisms Underlying Effect Induced by *E. Granulosus* {#s1_2}
-------------------------------------------------------

Despite the great efforts put by researchers, little is known about the mechanisms underlying the anticancer effect induced by *E. granulosus*. Several potential mechanisms have been proposed, including direct anticancer effect induced by parasite molecules and indirect anticancer effect through activation of host immune response ([**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}).

![Potential mechanisms underlying the anti-cancer effect induced in the acute stage of *Echinococcus granulosus* infection. In the acute stage, EgKI-1 release by oncosphere will potently null the neutrophil elastase and disrupt cell cycle, therefore inducing anticancer effect against several cancer types. Meanwhile, the mucin-type O-glycan of this parasite will be recognized by host immune system, thus activating innate and Th-1-polarized immune responses, which are protective against cancer.](fphar-10-01137-g001){#f1}

![Potential mechanisms underlying the anticancer effect induced in the chronic stage of *Echinococcus granulosus* infection. In the chronic stage, the content of hydatid cyst will be released into liver or other infection sites when the cyst dies or ruptures. Highly immunogenic content of hydatid cyst will quickly activate innate immunity and convert Th-2 response to Th-1 response, which are protective against cancer. AgB, another potent neutrophil elastase inhibitor highly expressed in the hydatid cyst, may exhibit anticancer effect through inhibition of neutrophil elastase and neutrophil chemotaxis. Meanwhile, the protoscolex may also play a role in the anticancer effect.](fphar-10-01137-g002){#f2}

Direct Anticancer Effect Induced by Parasite Molecules {#s1_3}
------------------------------------------------------

Several studies have suggested that *E. granulosus* could kill cancer cell or inhibit tumor growth. As noted above, protoscolex could induce cell death in WEHI-164 fibrosarcoma cell *in vitro* ([@B19]) and inhibit melanoma tumor growth *in vivo* ([@B16]). The specific molecules involved in this process, however, remain largely unclear. Notably, a study found that treatment with different hydatid molecules, especially the protoscolex excretory/secretory (ES) molecules, could increase the number of dead cells and/or decrease the number of alive cells in HeLa cell culture; meanwhile, treatment with the same molecules neither increase the number of dead cells nor decrease the number of alive cells in vero cell culture ([@B5]). Subsequently, another study found that injection of hydatid fluid (peritoneal or tumor margin) could decrease melanoma tumor size in C57 mouse model ([@B21]). However, the alum-based adjuvant employed in the latter study is potentially confounding ([@B56]), since alum may induce anticancer effect through selectively stimulation of Th2 immune response ([@B24]). Recently, a research group found that the Kunitz-type protease inhibitor EgKI-1, a potent chymotrypsin and neutrophil elastase inhibitor highly expressed by oncosphere of *E. granulosus* ([@B54]), could inhibit several human cancers from growth and migration, probably through disrupting cell cycle and inducing apoptosis of cancer cells, without affecting normal cell growth *in vitro* ([@B55]). Meanwhile, EgKI-1 treatment could restrict experimental triple negative breast cancer growth in a BABL/c mouse model. The specific mechanism underlying this effect still demands further exploring. A possible explanation is that EgKI-1 may decrease cancer cell migration *via* potent inhibition of neutrophil elastase, which plays a pivotal role in cancer metastasis ([@B76]). Being another potent neutrophil elastase inhibitor highly expressed in the hydatid cyst, it has been hypothesized that Antigen B (AgB) may be responsible for the anticancer effect induced during chronic state of infection. Recently, another study explored the anticancer potential of several hydatid fluid antigens, including AgB, glycolipid, glycoprotein, and 78 kDa fractions in breast cancer cell lines. Compared with the other molecules, less apoptosis was observed after treatment with AgB fraction ([@B18]). Therefore, the possible role of AgB requires further exploring. In general, available evidence suggested that the molecules from the hydatid cyst, especially the ES molecules, are potentially responsible for the anticancer effect of this parasite.

Indirect Anticancer Effect Through Activation of Host Immune System {#s1_4}
-------------------------------------------------------------------

As noted above, anticancer effect has been seen in various parasites infection. Similar with parasites infection, cancer cells could also trigger innate and adaptive immunity in the process of development ([@B66]). Therefore, it has been hypothesized that parasites may induce indirect anticancer activities *via* boosting host immune system when chronically infected at a low density ([@B20]), i.e., parasites infection may play as negative regulator of cancer through reactivation of host immune system ([@B13]).

In favor of this hypothesis, antigen similarity between several parasites and certain cancer types has been reported, especially the cancer-associated mucin-type *O*-glycans ([@B52]), thus allowing crosstalk between parasites and carcinomas to ensue. For example, *S. mansoni* can express the Tn antigen ([@B50]), which is associated with many cancer types (including bladder, cervix, colon, ovary, gastric, lung, and prostate cancer) and plays an important role in cancer metastasis and evasion from immunosurveillance ([@B27]). Meanwhile, the Tk antigen, which is strongly expressed at the surface of a significant proportion of human colorectal carcinomas ([@B43]), has been detected in *Taenia hydatigena*, *Taenia crassiceps*, and *Mesocestoides vogae* ([@B69]). In the case of *E. granulosus*, the initial evidence of common antigen shared with cancers came from a report published in late 1970s, which found that an immunoelectrophoresis test with hydatid fluid and serum from a patient with pulmonary carcinoma resulted in an intense precipitin band ([@B72]). Thereafter, different research groups have independently reported the antigen similarity between *E. granulosus* and several cancer types, especially the mucin-type O-glycans. As an example, cancer-associated Tn antigen and Sialyl-Tn (sTn) antigen have been detected in both larva and adult worm extracts and in sera from patients with hydatid disease ([@B4]). In addition, TF antigen has been characterized in adult worm ([@B14]). Besides, common antigens other than mucin-type *O*-glycans have also been detected. For example, a nonglycosylated 27 kDa molecule was shared by human breast cancer and *E. granulosus* ([@B58]). Similarly, the hot shock protein 70 of *E. granulosus* displayed 60% homology with the mortalin of CT26 colon cancer cell ([@B8]). Moreover, it has been demonstrated that the common antigens shared by E. granulosus and cancers could induce immunological cross-reaction. For example, it has been demonstrated that antigens from hydatid cyst could react with sera from patients with breast cancer, while antisera raised against laminated and germinal layers of hydatid cyst could react with ES products of cancer cell ([@B17]). In addition, a 40-kDa antigen from hydatid fluid could react with sera from patients with breast cancer, while monoclonal antibody raised against this 40-kDa antigen could react with breast cancer cell (but cell growth was unaffected) ([@B59]). Altogether, it is reasonable to hypothesize that *E. granulosus* may exhibit anticancer effect through adaptive immunity induced by common antigens.

Previous studies have demonstrated that both cellular immunity and humoral immunity induced by protozoan parasite *Trypanosoma cruzi* are protective against several cancer types in mice model ([@B33]; [@B74]; [@B77]). In the case of *E. granulosus*, however, it is yet unclear which kind of immunity is more important in the anticancer effect. In the paradigm of onco-immunology, it has been recognized that Th1-polarized response plays pivotal role in killing cancer cell and inhibiting tumor growth, whereas Th2-polarized response promotes tumor progression and metastasis ([@B61]; [@B73]). As for *E. granulosus*, the immunity induced by parasite varies at different infection stages: 1) During oncosphere invasion, a Th1-polarized response will dominate; 2) in the process of cyst formation and growth, a Th2-polarized response will gradually take in charge; 3) when cyst ruptures or dies, the Th2-polarized response will be rapidly taken over by Th1-polarized response ([@B75]; [@B29]). Therefore, it has been hypothesized that the anticancer effect may come from the Th1-polarized response induced at specific stages of infection ([@B65]). In addition, this may provide an explanation for the contradictive results from some epidemiological investigation ([@B51]) and laboratory research ([@B68]), which showed that CE may promote cancer development and progression.

There are some evidence that support the role of humoral immunity in the anticancer effect induced by *E. granulosus*. As noted above, sera from patients with hydatid disease was cytotoxic to lung cancer cell line but had no effect on fibroblast cells ([@B35]). However, the humoral immunity seems unimportant in the anticancer effect induced by *E. granulosus* in subsequent studies. As an example, antibody against Tn-like peptide from *E. granulosus* scarcely reacted with mammary adenocarcinoma cell line TA3/Ha and pancreatic adenocarcinoma cell line Panc02 (both of which strongly express Tn antigen), despite the peptide induced high level of antibody production; meanwhile, high level of interferon gamma (IFN-γ) was detected in mice immunized with this peptide, while interleukin (IL)-5 and IL-17 were not detected, indicating a Th1-dominant response ([@B49]). Similarly, immunization of mice bearing melanoma cancer with hydatid cyst antigens resulted in inhibition of tumor growth and IFN-γ production ([@B63]). Moreover, the monoclonal antibody raised against the 40-kDa antigen hydatid fluid mentioned above could not restrict breast cancer cell growth *in vitro*, even though it could react with breast cancer cell ([@B59]). Recently, a study found that passive transfer of antisera against hydatid fluid, protoscolex antigen, or cyst wall antigen did not affect melanoma tumor growth in recipient mice that had already been challenged by melanoma cells ([@B22]). On the other hand, passive transfer of spleen cells from mice immunized with hydatid cyst, hydatid fluid, or protoscolex to recipient mice would lead to significant reduction in melanoma tumor size and tumor growth rate ([@B53]; [@B22]). Therefore, Th1-polarized response are more likely to be responsible for the anticancer effect induced by *E. granulosus*.

Besides adaptive immunity, the study noted above also detected high level of natural killer cell activation, thus indicating a role of innate immunity in the anticancer effect ([@B49]). However, a definite conclusion cannot be reached in the current stage due to lack of evidence.

In summary, *E. granulosus* may induce anticancer effect through direct anticancer effect, i.e., secreting various molecules with cancer killing effect, and indirect anticancer effect, i.e. activating host immune response (Th1-polarized response in particular). However, more efforts are required to shed further light on the mechanisms underlying this extraordinary effect.

Implication in Cancer Immunotherapy {#s1_5}
-----------------------------------

In the long-lasting campaign against cancer, four general approaches have been developed: surgery, chemotherapy, radiotherapy, and most recently, immunotherapy, which has evolved into a promising cancer treatment modality ([@B26]). Inspired by the victory achieved with ICIs in the last decade, oncologists and immunologists have made every endeavor to secure further success. However, the success achieved with ICIs is still limited, thus demanding more directions to be explored. The incidental discovery of anticancer effect induced by *E. granulosus* infection have gained much focus. Understanding the underling mechanisms may provide some new insights for immunotherapy orchestration.

Echinococcal Molecules With Anticancer Potential {#s1_6}
------------------------------------------------

Available evidences have led to a hypothesis that *E. granulosus* may induce anticancer effect through hydatid molecules, especially the protoscolex ES molecules. Although the specific molecules and the underlying mechanisms remain largely unknown, EgKI-1, a potent chymotrypsin and neutrophil elastase inhibitor highly expressed by *E. granulosus* ([@B54]), was able to induce anticancer effect both *in vitro* and in animal models ([@B55]). In addition to the potent inhibitory effect on neutrophil elastase, which plays a crucial role in cancer metastasis, EgKI-1 can also induce anticancer effect by directly inhibiting tumor growth, probably through disrupting cell cycle progression, thus increasing cancer cell apoptosis. Meanwhile, the relatively low molecular weight of EgKI-1 (\< 10 kDa) may allow it to penetrate tumor tissues effectively, thus facilitating its interaction with malignant cells. Therefore, EgKI-1 seems to be a promising therapeutic molecule against cancer, which may be considered in future treatment development.

Echinococcal Antigens as Cancer Vaccine for Immunotherapy {#s1_7}
---------------------------------------------------------

Successful ICIs treatment depends not only on the expression of checkpoint protein but also the immunogenicity of the cancer cells, i.e., whether the tumor is "immune competent" or "immune deficient" ([@B39]). "Immune competent" means that the immunogenicity of cancer cell is strong enough to induce immune response of infiltrating T cells, which are unable to function normally due to checkpoint blockade or other immunoregulatory mechanisms ([@B47]; [@B60]); in direct contrast, "immune deficient" means that the immunogenicity of cancer cell is not sufficient to be recognized, thus enabling tumor to escape from host immune surveillance even after the checkpoint blockade has been relieved by ICIs ([@B32]; [@B67]).

After near 40 years of extensive research with only limited success, it is now believed that cancer vaccine may have the potential to convert immune-deficient tumor amenable to ICIs treatment through activation of T cell immunity ([@B41]; [@B42]). In this context, an ideal cancer vaccine should be, first, able to stimulate strong Th-1 response specifically (since Th-2 response may facilitate cancer progression and metastasis), and second, tumor-specific (inducing adaptive immunity specifically against cancer cells while sparing normal cells). Many tumor-specific antigens have been identified and exploited. Most of them, however, cannot trigger proper and effective immune response ([@B12]), including the tumor associated mucin-type O-glycans Tn, sTn, and T antigen ([@B27]), which are almost exclusively found in cancer cells and have been widely employed in cancer diagnosis and prognosis prediction ([@B36]). Notably, an sTn-based vaccine failed to benefit women with metastatic breast cancer despite high level of specific immunoglobulin G production and immunoglobulin M-to-immunoglobulin G seroconversion in a phase III multicenter study ([@B44]). A Th-2 dominant response may be an explanation for the failure of this vaccine, thus highlighting the importance of a Th-1-dominant response.

As noted above, the mucin-type O-glycans have already been detected both in adult and larval stage of *E. granulosus* and in patients with CE ([@B4]; [@B14]). On the other hand, accumulating evidences have demonstrated that hydatic cyst antigens can induce anticancer effect against several cancer types *in vitro* and in murine models ([@B5]; [@B21]; [@B63]; [@B22]). Furthermore, immunization of mice with echinococcal antigens, whether Tn-like peptide or crude hydatid cyst antigens, resulted in high level of IFN-γ production, indicating a Th-1-polarized response ([@B49]). Taken together, these findings attempt us to hypothesize that the hydatid cyst antigens, especially the mucin like O-glycans, may induce anticancer effect through activation of Th-1-polarized immune response. Therefore, the mucin-like O-glycans of *E. granulosus* may be considered as potential candidate in future vaccine design. Since there are great differences between human and murine immune system, additional studies are required to verify this hypothesis.

Conclusion {#s2}
==========

Accumulating evidences have suggested that the canine tapeworm *E. granulosus* can induce anticancer effect against several cancer types *in vitro* and in murine model, presumably through activating Th-1-polarized immune response with common antigens, especially the mucin-type O-glycans, and secreting molecules with anticancer potential, EgKI-1 in particular. Hopefully, these findings may provide some new insights into immunotherapy and replenish our arsenal against cancer. With a new era of immunotherapy at dawn, further studies are required to shed further lights on the mechanism underling the Th-1 response induced by mucin-type O-glycans and to identify additional ES products with anticancer potential. In addition to anticancer effect, several research groups have reported that *E. granulosus* could not only provide protective effect against *Taenia multiceps* infection in sheep ([@B28]) but also against experimental colitis ([@B62]; [@B37]) and airway inflammation ([@B70]; [@B38]). The exact mechanism underlying these protective effects remain largely unknown, possibly related to antigen similarity and immunomodulatory effect from echinococcal molecules, which are also worthy of further exploring.
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